AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2025
Sep 4, 2025
31100_dirs_2025-09-04_eb175e51-fe3f-4a03-981a-183e1363460b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-09-02
Reporting Person: Dhaliwal Harpreet S. (Chief Technical Ops Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-02 | Common Stock | F | 291 | $31.56 | Disposed | 36121 | Direct |
| 2025-09-02 | Common Stock | F | 783 | $31.56 | Disposed | 35338 | Direct |
| 2025-09-02 | Common Stock | F | 464 | $31.56 | Disposed | 34874 | Direct |
Footnotes
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Capital/Financing Update
2026
Feb 24